Breast cancer prognosis and management for both men and women are reliant upon
estrogen receptor alpha (ERα) and progesterone receptor (PR) expression to inform …

Male breast cancer remains understudied despite evidence of rising incidence. Using a co-
ordinated multi-centre approach, we present the first large scale biomarker study to define …

PURPOSE: Hormone receptor expression (presence-positive or absence-negative) may
reflect different stages of one disease or different breast cancer types. Determining whether …

Introduction Estrogen receptor (ER) and progesterone receptor (PR) testing are performed in
the evaluation of breast cancer. While the clinical utility of ER as a predictive biomarker to …

Despite evidence indicating the dominance of cell-of-origin signatures in molecular tumor
patterns, translating these genome-wide patterns into actionable insights has been …

Estrogen signaling plays an essential role in breast cancer progression, and estrogen
receptor (ER) status has long been a marker of hormone responsiveness. However, ER …

Male breast cancer (MBC) is a poorly characterized disease because of its rarity. Clinical
management is based on results obtained from randomized trials conducted in women …

Breast cancer subtypes defined by estrogen receptor (ER), progesterone receptor (PR), and
HER2 expression are biologically distinct and thus, may have distinct etiologies. In …

Various subtypes of breast cancer defined by estrogen receptor (ER), progesterone receptor
(PR), and HER2 exhibit etiologic differences in reproductive factors, but associations with …

The cost of next-generation sequencing technologies is rapidly declining, making RNA-seq-
based gene expression profiling (GEP) an affordable technique for predicting receptor …